MONTREAL, March 20 /CNW Telbec/ - (TSX.V: BUG) - Biophage Pharma today
announced that Mr. Louis Guindon has resigned as Chief Financial Officer of
the company effective March 19, 2008. Mr. Guindon intends to keep assisting
the company on a consultancy basis. Biophage is presently considering
different options for his replacement on an interim basis.
"The Board of Directors and Management wish to thank Mr. Guindon for his
excellent approach in rationalizing expenses and strengthening the quality of
the company's accounting practice over the past year. The scientific and
technical staff joins the Board of Directors in wishing him the best of luck
in his future career." concluded Dr Mandeville.
About Biophage Pharma Inc.
Biophage is a Canadian biotechnology company focused on the development
of innovative phage-based products and technologies for the detection,
prevention and control of bacterial infections. Biophage also operates the
Immunotox Labs division, which provides services in Immunogenicity and
Immunotoxicity, screening for Beryllium sensitization (the BeLPT test) and
exclusive MELISA(R) for the detection of sensitization to more than
200 different allergens including metals, penicillin, gluten, pollens and more
recently Lyme disease (Boreliosis).
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
For further information:
For further information: Rosemonde Mandeville, M.B., Ch.B., PhD.,
President and CEO, Biophage Pharma Inc., (514) 496-1488,